Functional reconstitution of defective myeloid dendritic cells in chronic hepatitis C infection on successful antiviral treatment

Liver International

Volumn 32, Issue 7, 2012, Pages 1128-1137

  Rana, Deepa ^a   Chawla, Yogesh K ^a   Duseja, Ajay ^a   Dhiman, Radhakrishan ^a   Arora, Sunil K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Chronic hepatitis c; Immunomodulation; Mo dendritic cells; Peg interferon ribavirin; Sustained virological response

Indexed keywords

B7 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PEGINTERFERON ALPHA2B; RIBAVIRIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENDOCYTOSIS; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HUMAN; HUMAN CELL; MALE; MYELOID DENDRITIC CELL; PHAGOCYTOSIS; PREMEDICATION; TREATMENT RESPONSE; UPREGULATION;

ADULT; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; ANTIVIRAL AGENTS; DENDRITIC CELLS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMMUNOGLOBULINS; INTERFERON-ALPHA; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MYELOID CELLS; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME; UP-REGULATION; YOUNG ADULT;

EID: 84863512095     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02754.x     Document Type: Article

References (28)

1. Nakai K, Win KM, Oo SS, Arakawa Y, Abe K. Molecular characteristic-based epidemiology of hepatitis B, C, and E viruses and GB virus C/hepatitis G virus in Myanmar. J Clin Microbiol 2001; 39: 1536-9.
2. Mukhopadhya A. Hepatitis C in India. J Biosci 2008; 33: 465-73.
3. Singh S, Malhotra V, Sarin SK. Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India. Indian J Med Res 2004; 119: 145-8.
4. Simmonds P, Bukh J, Combet C, et al. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005; 42: 962-73.
5. Farrell GC. New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007; 22: 607-10.
6. Dev AT, McCaw R, Sundararajan V, Bowden S, Sievert W. Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes and race on treatment outcome. Hepatology 2002; 36: 1259-65.
7. Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ. Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 2004; 117: 163-8.
8. Kanto T, Hyashi N, Takehara T, et al. Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. J Immunol 1999; 162: 5584-91.
9. Auffermann-Gretzinger S, Keeffe E, Levy S. Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 2001; 97: 3171-6.
10. Bain C, Fatmi A, Zoulim F, et al. Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology 2001; 120: 512-24.
11. Kaimori A, Kanto T, Kwang Limn C, et al. Pseudotype hepatitis C virus enters immature myeloid dendritic cells through the interaction with lectin. Virology 2004; 324: 74-83.
12. Miyazaki M, Kanto T, Inoue M, et al. Impaired cytokine response in myeloid dendritic cells in chronic hepatitis C virus infection regardless of enhanced expression of Toll-like receptors and retinoic acid inducible gene-I. J Med Virol 2008; 80: 980-8.
13. Kanto TIM, Miyatake H, Sato A, et al. Reduced numbers and impaired ability of myeloid and plasmacytoid dendritic cells to polarize T helper cells in chronic hepatitis C virus infection. J Infect Dis 2004; 190: 1919-26.
14. Longman RSTA, Jacobson IM, Albert ML, Rice CM. Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. Blood 2004; 103: 1026-9.
15. Larsson MBE, Grakoui A, Shoukry N, et al. Lack of phenotypic and functional impairment in dendritic cells from chimpanzees chronically infected with hepatitis C virus. J Virol 2004; 78: 6151-61.
16. Mengshol JA, Golden-Mason L, Castelblanco N, et al. Impaired plasmacytoid dendritic cell maturation and differential chemotaxis in chronic hepatitis C virus: associations with antiviral treatment outcomes. Gut 2009; 58: 964-73.
17. Perrella A, Atripaldi L, Bellopede P, et al. Flow cytometry assay of myeloid dendritic cells (mDCs) in peripheral blood during acute hepatitis C: possible pathogenetic mechanisms. World J Gastroenterol 2006; 12: 1105-9.
18. Piccioli D, Tavarini S, Nuti S, et al. Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. J Hepatol 2005; 42: 61-67.
19. Szabo G, Dolganiuc A. Subversion of plasmacytoid and myeloid dendritic cell functions in chronic HCV infection. Immunobiology 2005; 210: 237-47.
20. Tsubouchi E, Akbar SM, Horiike N, Onji M. Infection and dysfunction of circulating blood dendritic cells and their subsets in chronic hepatitis C virus infection. J Gastroenterol 2004; 39: 754-62.
21. Yakushijin T, Kanto T, Inoue M, et al. Reduced expression and functional impairment of Toll-like receptor 2 on dendritic cells in chronic hepatitis C virus infection. Hepatol Res 2006; 34: 156-62.
22. MacDonald AJ, Semper AE, Libri NA, Rosenberg WMC. Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells A. J Clin Exp Immunol 2007; 148: 494-500.
23. Barnes E, Salio M, Cerundolo V, et al. Impact of alpha interferon and ribavirin on the function of maturing dendritic cells. Antimicrob Agents Chemother 2004; 48: 3382-9.
24. Miyatake H, Kanto T, Inoue M, et al. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection. J Viral Hepat 2007; 14: 404-12.
25. Rigopoulou EI, Abbott WG, Haigh P. Blocking of interleukin-10 receptor - a novel approach to stimulate T-helper cell type 1 responses to hepatitis C virus. Clin Immunol 2005; 117: 57-64.
26. Yu ML, Dai CY, Huang JF, et al. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-93.
27. Yu ML, Dai CY, Huang JF, et al. A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C. Gut 2007; 56: 553-9.
28. Yu JW, Wang GQ, Sun LJ, Li XG, Li SC. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 2007; 22: 832-6.